EPO and anemia (phenotype): Another randomized clinical trial designed to evaluate the superiority of recombinant human erythropoietin to PRBC transfusion in treating anemia in patients with cervical cancer was halted prematurely owing to concerns regarding increased thromboembolic events with recombinant human erythropoietin.